• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

CVAC Systems and TempusClinic Partner to Study the Potential Value of The CVAC Process in Managing and Treating Diabetes, Insulin Resistance, and Metabolic Syndrome

Posted on: Monday, 25 September 2006, 15:00 CDT

CVAC Systems, Inc. (www.cvacsystems.com)

announced today an agreement with Los Gatos, Calif.-based TempusClinic

to study the potential value of the CVAC process in managing and

treating diabetes, insulin resistance, and metabolic syndrome. The study

is expected to commence next month.

CVAC Systems has developed a new, noninvasive modality for the treatment

of metabolic derangement, which includes diabetes, insulin resistance,

and metabolic syndrome. Data published in respected peer-review-ed

journals have shown significant improvement in metabolic insulin

efficiency and glycemic control (in animals and man) with the use of

intermittent hypoxic (high altitude) training (IHT). Cyclic Variations

in Altitude Conditioning (CVAC) is a scientifically validated IHT

process which triggers the human body's

natural high-altitude adaptation response. CVAC, however, produces the

beneficial effects of high-altitude adaptation via IHT while

significantly reducing the required exposure time for IHT. Other

techniques providing IHT require exposure ranging from 21 to 84 hours

per week; CVAC exposures require less than 4.5 hours per week.

"There are more than 90 million individuals in

the U.S. and some 200 million worldwide who suffer from metabolic

derangement," said Allen J. Ruszkowski,

President and CEO of CVAC Systems. "The cost

of treating diabetes alone, which is just one of the forms of metabolic

derangement, is over $125 billion annually in the U.S. In addition,

there are an estimated 50 million Americans with metabolic syndrome,

another form of metabolic derangement, who have a fivefold increased

probability of developing diabetes and a twofold increased risk in

developing cardiovascular disease. Currently, physicians lack a

successful treatment regimen to help their patients other than

browbeating the patient to change diet, lose weight and exercise, which

has very poor compliance."

"TempusClinic uses a four-part integrated

program to help our clients achieve metabolic turnaround. We combine the

best of today's science, the most advanced

technologies, and the most natural means by which our clients may

achieve their health and fitness goals,"

added Mike Nichols, M.D., CEO and Founder of TempusClinic. "We

are, therefore, very interested in studying the CVAC process, which we

believe will go hand-in-hand with our programs. We are always looking

for scientifically validated non-invasive, non-toxic approaches to

health advancement," said Dr. Nichols.

About TempusClinic

Founded in 2001, TempusClinic is the leader in personalized preventative

health care. Located in Los Gatos, Calif., TempusClinic is comprised of

a team of renowned physicians, fitness trainers, and medical

professionals who are committed to health excellence in a caring,

supportive and educational environment. Dr. Mike Nichols background in

scientific theory construction at the University of Chicago, where he

obtained his first graduate degree in the Philosophy of Science, led him

to question current medical approaches to complex medical problems and

led him eventually to found the TempusClinic. His medical degree is from

Loyola University of Chicago and residency from Stanford University. He

practiced medicine for 20 years prior to developing TempusClinic

About CVAC Systems

CVAC Systems, Inc., headquartered in Temecula, Calif., is privately

funded and is seeking to place CVAC instruments (pressure vessels) at

key luminary research sites for the development of several

patent-pending applications such as performance enhancement, disease

prevention, therapy and advanced health. For these plans, the Company is

seeking a first-round venture/institutional financing.

Please note: The information contained within this document is intended

for prospective investors only, and is not intended for patients or

health care providers. Any references to therapeutic applications are

for discussion and research purposes only.

Source: Business Wire

More News in this Category